๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Small-molecule release from poly(D,L-lactide)/poly(D,L-lactide-co-glycolide) composite microparticles

โœ Scribed by Emily J. Pollauf; Kyekyoon Kevin Kim; Daniel W. Pack


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
402 KB
Volume
94
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

โœฆ Synopsis


Addition of biodegradable polymer shells surrounding polymeric, drugloaded microparticles offers the opportunity to control drug release rates. A novel fabrication method was used to produce microparticles with precise control of particle diameter and the thickness of the polymer shell. The effect of shell thickness on release of a model drug, piroxicam, has been clearly shown for 2-to 15-mm thick shells of poly(D,Llactide) (PDLL) surrounding a poly(D,L-lactide-co-glycolide) (PLG) core and compared to pure PLG microspheres loaded with piroxicam. Furthermore, the core-shell microparticles are compared to microspheres containing blended polymers in the same mass ratios to demonstrate the importance of the core-shell morphology. Combining PDLL(PLG) microcapsules of different shell thicknesses allows nearly constant release rates to be attained for a period of 6 weeks.


๐Ÿ“œ SIMILAR VOLUMES


Poly(para-dioxanone)/poly(D,L-lactide) b
โœ Wei Bai; Qing Li; Liu-Yun Jiang; Zhi-Ping Zhang; Shen-Lan Zhang; Cheng-Dong Xion ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 421 KB ๐Ÿ‘ 1 views

## Abstract The effect of poly(D,Lโ€lactideโ€__co__โ€__para__โ€dioxanone) (PLADO) as the compatibilizer on the properties of the blend of poly(__para__โ€dioxanone) (PPDO) and poly(D,Lโ€lactide) (PDLLA) has been investigated. The 80/20 PPDO/PDLLA blends containing from 1% to 10% of random copolymer PLADO

Nanoparticles of poly(D,L-lactide)/metho
โœ Yuancai Dong; Si-Shen Feng ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 269 KB

## Abstract Paclitaxel is one of the best antineoplastic drugs found in nature in the past decades, which has excellent therapeutic effects against a wide spectrum of cancers. Because of its high hydrophobicity, Cremophor EL has to be used as adjuvant in its clinical dosage form (Taxolยฎ), which has